Literature DB >> 32067353

European Society of ColoProctology: guideline for haemorrhoidal disease.

R R van Tol1, J Kleijnen2, A J M Watson3, J Jongen4, D F Altomare5, N Qvist6, T Higuero7, J W M Muris8, S O Breukink1.   

Abstract

AIM: The goal of this European Society of ColoProctology project was to establish a multidisciplinary, international guideline for haemorrhoidal disease (HD) and to provide guidance on the most effective (surgical) treatment for patients with HD.
METHODS: The development process consisted of six phases. In phase one we defined the scope of the guideline. The patient population included patients with all stages of haemorrhoids. The target group for the guideline was all practitioners treating patients with haemorrhoids and, in addition, healthcare workers and patients who desired information regarding the treatment management of HD. The guideline needed to address both the diagnosis of and the therapeutic modalities for HD. Phase two consisted of the compilation of the guideline development group (GDG). All clinical members needed to have affinity with the diagnosis and treatment of haemorrhoids. Further, attention was paid to the geographical distribution of the clinicians. Each GDG member identified at least one patient in their country who could read English to comment on the draft guideline. In phase three review questions were formulated, using a reversed process, starting with possible recommendations based on the GDG's knowledge. In phase four a literature search was performed in MEDLINE (Ovid), PubMed, Embase (Ovid) and the Cochrane Database of Systematic Reviews. The search was focused on existing systematic reviews addressing each review question, supplemented by other studies published after the time frame covered by the systematic reviews. In phase five data of the included papers were extracted by the surgical resident (RT) and checked by the methodologist (JK) and the GDG. If needed, meta-analysis of the systematic reviews was updated by the surgical resident and the methodologist using Review Manager. During phase six the GDG members decided what recommendations could be made based on the evidence found in the literature using GRADE.
RESULTS: There were six sections: (i) symptoms, diagnosis and classification; (ii) basic treatment; (iii) outpatient procedures; (iv) surgical interventions; (v) special situations; (vi) other surgical techniques. Thirty-four recommendations were formulated.
CONCLUSION: This international, multidisciplinary guideline provides an up to date and evidence based summary of the current knowledge of the management of HD and may serve as a useful guide for patients and clinicians. Colorectal Disease
© 2020 The Association of Coloproctology of Great Britain and Ireland.

Entities:  

Mesh:

Year:  2020        PMID: 32067353     DOI: 10.1111/codi.14975

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  18 in total

1.  Massive gastrointestinal bleeding after endoscopic rubber band ligation of internal hemorrhoids: A case report.

Authors:  Yu-Dong Jiang; Ying Liu; Jian-Di Wu; Gang-Ping Li; Jun Liu; Xiao-Hua Hou; Jun Song
Journal:  World J Clin Cases       Date:  2022-07-06       Impact factor: 1.534

2.  Tamponade dressing versus no dressing after haemorrhoidectomy: multicentre, randomized clinical trial.

Authors:  Mike Ralf Langenbach; Razvan-Valentin Florescu; Andreas Köhler; Jörg Barkus; Jörg-Peter Ritz; Eduart Quemalli; Robert Siegel; Hubert Zirngibl; Rolf Lefering; Lars Bönicke
Journal:  BJS Open       Date:  2022-05-02

3.  Is the Goligher classification a valid tool in clinical practice and research for hemorrhoidal disease?

Authors:  L Dekker; I J M Han-Geurts; U Grossi; G Gallo; R Veldkamp
Journal:  Tech Coloproctol       Date:  2022-02-09       Impact factor: 3.699

Review 4.  A Stepwise Proposal for Low-Grade Hemorrhoidal Disease: Injection Sclerotherapy as a First-Line Treatment and Rubber Band Ligation for Persistent Relapses.

Authors:  Roberta Tutino; Marco Massani; Leonel Jospin Kamdem Mambou; Paolina Venturelli; Immacolata Della Valle; Giuseppina Melfa; Matilde Micheli; Gaia Russo; Gregorio Scerrino; Sebastiano Bonventre; Gianfranco Cocorullo
Journal:  Front Surg       Date:  2022-01-10

5.  Risk factors for hemorrhoidal disease among healthy young and middle-aged Korean adults.

Authors:  Yun Soo Hong; Kyung Uk Jung; Sanjay Rampal; Di Zhao; Eliseo Guallar; Seungho Ryu; Yoosoo Chang; Hyung Ook Kim; Hungdai Kim; Ho-Kyung Chun; Chong Il Sohn; Hocheol Shin; Juhee Cho
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

Review 6.  Surgical Management of Hemorrhoidal Disease in Inflammatory Bowel Disease: A Systematic Review with Proportional Meta-Analysis.

Authors:  Ugo Grossi; Gaetano Gallo; Gian Luca Di Tanna; Umberto Bracale; Mattia Ballo; Elisa Galasso; Andrea Kazemi Nava; Martino Zucchella; Francesco Cinetto; Marcello Rattazzi; Carla Felice; Giacomo Zanus
Journal:  J Clin Med       Date:  2022-01-28       Impact factor: 4.241

7.  Early and midterm results of radiofrequency ablation (Rafaelo® procedure) for third-degree haemorrhoids: a prospective, two-centre study.

Authors:  S Tolksdorf; D Tübergen; C Vivaldi; M Pisek; F Klug; M Kemmerling; H Schäfer
Journal:  Tech Coloproctol       Date:  2022-03-19       Impact factor: 3.699

8.  Editorial: Haemorrhoidal Disease: Old Solutions and Future Perspectives.

Authors:  Sara Z Kuiper; Gaetano Gallo; Mario Trompetto; Arcangelo Picciariello; Stéphanie O Breukink
Journal:  Front Surg       Date:  2022-04-12

9.  Treatment of haemorrhoidal disease with micronized purified flavonoid fraction and sucralfate ointment.

Authors:  Antonino Amaturo; Massimo Meucci; Francesco Saverio Mari
Journal:  Acta Biomed       Date:  2020-03-19

10.  Preparation and In Vivo Evaluation of a Lidocaine Self-Nanoemulsifying Ointment with Glycerol Monostearate for Local Delivery.

Authors:  Ji-Hyun Kang; Kwang-Hwi Yoo; Hyo-Young Park; Seung-Min Hyun; Sang-Duk Han; Dong-Wook Kim; Chun-Woong Park
Journal:  Pharmaceutics       Date:  2021-09-14       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.